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Supervised Injection Facilities
Abstract
Injection drug use once accounted for half of the new HIV cases each year in Philadelphia. Today, it accounts
for less than 6%. This achievement is the result, in large part, of increased access to sterile syringes through
needle exchange at Prevention Point Philadelphia. But while tremendous strides have been made in reducing
the HIV risk for people who inject drugs (PWID), the story with respect to skin and soft tissue infection
(SSTI) and overdose is grim. SSTIs are life-threatening, painful, and remain common among PWID. Rates of
fatal overdose, meanwhile, have skyrocketed in recent years, resulting in 907 deaths in 2016 and over 1200 in
2017. Trends for injection-related HIV and injection-related infection and overdose have taken different
trajectories because access to sterile injection materials only addresses a portion of the risk environment for
injection drug use. Avoiding SSTIs is hard, even with a sterile syringe, when injecting in poorly lit, cold, dirty
or otherwise unhygienic spaces.
Reversing an overdose is possible with naloxone, but there has to be someone to administer it, and PWID
often inject in secluded spaces. Some evidence also suggests that overdose is more likely when PWID inject
hurriedly – from fear of assault or arrest – and without the opportunity to taste and control dosing.
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BACKGROUND
Injection drug use once accounted for 
half of the new HIV cases each year in 
Philadelphia. Today, it accounts for less 
than 6%1. This achievement is the result, 
in large part, of increased access to 
sterile syringes through needle exchange 
at Prevention Point Philadelphia. But 
while tremendous strides have been 
made in reducing the HIV risk for people 
who inject drugs (PWID), the story with 
respect to skin and soft tissue infection 
(SSTI) and overdose is grim. SSTIs are 
life-threatening, painful, and remain 
common among PWID2. Rates of fatal 
overdose, meanwhile, have skyrocketed 
in recent years, resulting in 907 deaths in 
2016 and over 1200 in 2017.
Trends for injection-related HIV and 
injection-related infection and overdose 
have taken different trajectories because 
access to sterile injection materials 
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Figure 1. Insite (Photo: Vancouver Coastal Health) 
only addresses a portion of the risk 
environment for injection drug use3. 
Avoiding SSTIs is hard, even with a sterile 
syringe, when injecting in poorly lit, cold, 
dirty or otherwise unhygienic spaces.
Reversing an overdose is possible with 
naloxone, but there has to be someone 
to administer it, and PWID often inject 
in secluded spaces. Some evidence also 
suggests that overdose is more likely 
when PWID inject hurriedly – from fear 
of assault or arrest – and without the 
opportunity to taste and control dosing4.
SIF: A HARM REDUCTION 
APPROACH 
Supervised Injection Facilities (SIFs) 
provide hygienic spaces and clinical 
supervision for injection drug use.  
Supervising health professionals 
advise about injection-related harms, 
provide clean injecting supplies, reverse 
overdoses, and provide linkages to 
medical and social services. SIFs are 
predicated on the harm reduction 
principle of meeting people in need 
“where they are.”  They are especially 
valuable, in this regard, for reaching 
vulnerable populations. SIFs have existed 
for over 3 decades in Europe, and for 
over a decade each in Australia and 
Canada. There are over 100 facilities in 
operation globally.   
Insite is North America’s first government 
authorized SIF. It opened in 2003 in 
Vancouver’s Lower East Side. The facility 
provides injection booths (see figure 1) 
where clients use pre-obtained drugs 
under staff supervision and with free 
injection equipment. Staff are available 
to reverse overdoses and provide other 
healthcare services. Insite offers onsite 
detoxification services and long-term 
recovery treatment and housing5.
“Individual and community 
harms associated with injecting 
drugs are fundamentally 
constituted by the fact that many 
people who inject drugs lack a 
clean, comfortable, and secure 
place to inject. Setting aside the 
evidence supporting SIFs, which 
is abundant, consistent and 
positive, providing such a place 
just makes sense.”
—CPHI Senior Fellow,  
Evan Anderson JD, PhD  
Written by Ruth Shefner, MSW, Colleen McGrath, and Meghana Sharma with consultation from Evan 
Anderson JD, PhD and Benjamin Cocchiaro MD, MPH
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EVIDENCE SUPPORTING SIFS
Effects on PWID Health:  
PWID who use SIFS report less frequent public injection, less syringe sharing, and 
more uptake in addiction treatment. Meta-analyses suggest that frequent SIF use is 
associated with an almost 70% reduction in syringe sharing. Evidence also suggests 
that SIF users are more likely to engage in non-injection-related health behaviour, such 
as increased condom use and increased use of medical care and social services. 
SIFs also prevent fatal overdose among PWID. Since Insite opened in 2003, there has 
not been a single fatal overdose at the facility, and overdose rates have declined 35% 
around the facility and 9% city-wide5. Similar findings have been reported at SIFs 
elsewhere. 
Effects on Community Health: 
SIFs have well established benefits for community health and order. The opening of 
Insite was associated with a significant decrease in public injecting, publicly-discarded 
syringes, and injection-related litter. Similar reductions were reported in Australia 
and Spain by residents, business owners, and PWID themselves. There is no evidence 
that implementing a SIF increases crime; in fact, six studies conducted in Canada and 
Australia found no change in public order and safety. A recent study also indicates that 
Insite has helped to reduce harmful interactions between PWID and police. 
Economic Effects:  
The economic case for SIFs is substantial. Start-up and operating costs are small 
compared to the cost of providing reactive care for PWID with otherwise unmet needs. 
Medical referral services available at Insite were associated with a substantial decrease 
in hospital length of stay; decreased HIV transmission rates alone save health systems 
as much as $6,000,000 CAD per year, an incremental cost-effectiveness ratio of $10,763 
CAD per DAY6. 
Obstacles and Opportunities:
There are no officially sanctioned facilities currently operating in the U.S. However, 
there are some unsanctioned facilities, and Boston has adopted a Supportive Place for 
Observation and Treatment (SPOT) that offers “engagement, support, [and] medical 
monitoring” for “8-10 individuals at a time who are over-sedated from the use of 
substances”7. Evaluations of these facilities are just emerging. A number of other cities, 
including Seattle, are actively planning to open a SIF8.
There are potential impediments. Federal 
law enforcement could challenge a SIF 
under a law that prohibits maintaining a 
space for the use of illicit drugs, although 
there are reasonable arguments that 
this law does not apply to a SIF. There 
are political “NIMBY-ism” challenges, 
too. Mobilizing community support and 
building coalitions across health, law 
enforcement and other stakeholders 
has been essential to successful 
implementation in other places. 
Despite these challenges, the public 
health arguments supporting the 
implementation of a SIF are growing. The 
Mayor’s Task Force to Combat the Opioid 
Epidemic recommended exploring the 
creation of a SIF last year9. The city has 
since sent health and law enforcement 
officials to Insite. Given Governor Wolf’s 
declaration that opioid use is a “disaster 
emergency” last week, the time for bold 
action has never been clearer.
Conclusion:
Opening an SIF is an essential 
component of a broader strategy to 
reduce injection-related harms, including 
overdose. 
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